Drug intelligence / Profile preview

Bellamine S

Development stage
Discontinued
Lead developer
Sandoz
Modality
Small Molecules
Administration
Oral
01

Overview

Bellamine S is a fixed-dose combination pharmaceutical product consisting of belladonna alkaloids, ergotamine tartrate, and phenobarbital, formulated as an oral extended-release tablet. It was historically utilized to manage a variety of conditions related to autonomic nervous system imbalance, most notably menopausal symptoms such as hot flashes, night sweats, and restlessness. The therapeutic effect is achieved through the synergistic actions of its three components: belladonna alkaloids provide anticholinergic activity to reduce glandular secretions and smooth muscle spasms; ergotamine tartrate acts as a vasoconstrictor on cranial blood vessels to treat vascular headaches; and phenobarbital serves as a sedative-hypnotic by enhancing GABAergic inhibition in the central nervous system. Due to the inclusion of a barbiturate, the drug carries risks of dependency and significant drug-drug interactions. Most formulations of this type have been discontinued or superseded by safer alternatives in modern clinical practice.

Brand names
Bellamine SBellergal-SBel-Phen-Ergot SPhenerbel-S
Other names
belladonna alkaloids + ergotamine tartrate + phenobarbital
02

Targets

ADRA1 (Alpha-1 adrenergic receptor family)GABRR (GABA-A receptor subunit rho)5-HT (Serotonin receptors)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Bellamine S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bellamine S.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call